MPS-C1M1: Introducing MPS and alpha-mannosidosis: Challenges in Diagnosis and Disease Management


➡️ Language: English
➡️ Duration: 70 min
Presenter: CHRISTINA LAMPE, University Hospital of Gießen, Germany

Learning ObjectivesPART 1: Introduction and Overview - What is MPS & Alpha-mannosidosis? (1) How to diagnose MPS/mannosidosis early (early, signs and symptoms) (2) Exploring the latest diagnostic options available to you (3) Reviewing the pathophysiology of MPS /mannosidosis PART 2: Red flags, Signs and symptom, the basis of diagnostics and when to refer if you suspect MPS or Alpha-mannosidosis (4) Examining the multi-systemic features of the diseases (5) Reviewing how to best follow up with patients - what are the immediate next steps? (6) Understanding the latest treatment options available to the patient 

Christina Lampe is Director of the Centre for Rare Diseases of the Department of Child Neurology, Epileptology and Social Medicine, Center for Paediatric and Adolescent Medicine, University Hospital of Gießen, Germany.


Register and directly watch the video. It's free...

Important Note: The information provided on this session is intended and designed for use by healthcare professionals with an interest in metabolic diseases, MPS and alpha-mannosidosis. All session viewers are required to register for the selected webinar before accessing the content. Content and views shared are solely those of the speaker.

The free-to-attend online course has been designed to help specialists and general paediatricians to reduce delay in the referral and diagnosis of patients with suspected MPS and alpha-mannosidosis, as well as improving the quality of patient’s lives who have already been diagnosed. On-time diagnosis is crucial for access to treatment and clinical trials, disease management and to access the proper care services at the earliest of the disease possible.

The course is an MPS Europe project in partnership with MetabERN and the Excellence in Pediatrics with the support of Abeona, Biomarin, Chiesi, Orchard Therapeutics, Regenxbio, Sanofi Genzyme, Takeda, and Ultragenyx. All modules of the course are independently organised by EIP in terms of content, topics and speakers appointed. 


get updates